首页> 外文期刊>British Journal of Pharmacology >Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib.
【24h】

Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib.

机译:体内一氧化氮合酶和环加氧酶的可诱导同工型之间的相互作用:使用选择性抑制剂1400W和塞来昔布的研究。

获取原文
获取原文并翻译 | 示例
       

摘要

1. Exposure of tissues to endotoxin (LPS) and/or cytokines leads to the induction of both inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2). It has previously been reported that there is 'cross-talk' between these two systems. However, such previous studies have been limited by the availability of highly selective inhibitors. Here we have investigated the interactions between iNOS and COX-2 in vivo using 1400W, an iNOS-selective inhibitor, and celecoxib, a COX-2-selective inhibitor. 2. Infusion of LPS to rats for 6 h caused a time-dependent increase in the plasma concentrations of 6 keto-prostaglandin F1alpha (6 keto-PGF1alpha) and nitriteitrate (NO2/NO3), consistent with the induction of iNOS and COX-2. Bolus injection of arachidonic acid (AA) at t=6 h resulted in a further increase of circulating levels of 6 keto-PGF1alpha in LPS-treated animals. 3. Treatment of rats with 1400W or the non-selective NOS inhibitor N(G)-monomethyl-L-arginine (L-NMMA) inhibited the increase in plasma NO2/NO3 but were both without effect on the plasma concentration of 6 keto-PGF1alpha before or after AA. 4. Treatment with the non-steroidal anti-inflammatory drugs (NSAIDs), A771726 or diclofenac, or with celecoxib significantly reduced the increase in circulating 6 keto-PGF1alpha caused by LPS, and the large increase in 6 keto-PGF1alpha following injection of AA. None of the COX inhibitors affected the increase in plasma NO2/NO3. Dexamethasone, however, significantly inhibited both the increase in 6 keto-PGF1alpha and the increase in NO2/NO3. 5. In conclusion, the use of selective inhibitors does not support the concept of cross talk in vivo between iNOS and COX-2.
机译:1.将组织暴露于内毒素(LPS)和/或细胞因子会导致诱导型一氧化氮合酶(iNOS)和环加氧酶2(COX-2)的诱导。以前有报道说这两个系统之间存在“串扰”。但是,这些先前的研究受到高度选择性抑制剂的限制。在这里,我们使用iNOS选择性抑制剂1400W和COX-2选择性抑制剂塞来昔布研究了iNOS和COX-2在体内的相互作用。 2.向大鼠输注LPS 6 h导致血浆中6 keto-prostaglandin F1alpha(6 keto-PGF1alpha)和亚硝酸盐/硝酸盐(NO2 / NO3)的血浆浓度随时间增加,这与诱导iNOS和COX一致-2。在t = 6 h时通过注射花生四烯酸(AA)进行小剂量注射,导致LPS处理动物体内6 keto-PGF1alpha的循环水平进一步升高。 3.用1400W或非选择性NOS抑制剂N(G)-单甲基-L-精氨酸(L-NMMA)处理的大鼠可抑制血浆NO2 / NO3的增加,但均不影响6-keto- AA之前或之后的PGF1alpha。 4.用非甾体类抗炎药(NSAIDs),A771726或双氯芬酸或塞来昔布治疗可显着降低LPS引起的循环6 keto-PGF1alpha的增加,以及注射AA后6 keto-PGF1alpha的大量增加。没有一种COX抑制剂影响血浆NO2 / NO3的增加。然而,地塞米松显着抑制6 keto-PGF1alpha的增加和NO2 / NO3的增加。 5.总之,选择性抑制剂的使用不支持iNOS和COX-2之间的体内串扰概念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号